Freedom Broker lifted its price target on Electromed to $50 from $45, maintaining a Buy rating as the medical device maker’s expanding margins underpin the upgrade.
The stock was trading at $32.20 at the time of the analysis, up 90% over the past year, with a market capitalization of $270 million. Freedom Broker cited Electromed’s fiscal 2026 outlook, which projects revenue growth of 15.3% alongside an operating margin expansion of more than 370 basis points to 18.8%.
The brokerage highlighted the company’s direct homecare segment, where average productivity per representative reached a record $1.145 million, exceeding management’s target range. Gross margins have remained stable at 78.5% for over a year despite inflationary pressures on electronics and freight costs. Electromed also reported a current ratio of 4.69 and a return on assets of 18.8%.
Electromed’s fourth-quarter fiscal 2026 results showed earnings per share of $0.39, outperforming the consensus estimate of $0.31, while revenue totaled $19.41 million, slightly below the expected $19.5 million. The company marked its 15th consecutive period of annual revenue and earnings growth.
The upgrade follows Electromed’s announcement that its CEO will retire, introducing transition risks as the board searches for a successor. Growth has been driven by expanded payer coverage and targeted campaigns for high-diagnosis physicians, though sales softened in the hospital segment.
